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Abstract
Background: Chronic kidney disease (CKD) is associated with an increased mortality rate, risk of cardiovascular
events and morbidity. Impaired renal function is common in elderly patients, and their glomerular filtration rate
(GFR) should be taken into account when prescribing renally excreted drugs. In a hospital care setting the GFR may
fluctuate substantially, so that the renal function group and therefore the recommended dose, can change within a
few days. The magnitude and prevalence of the fluctuation of renal function in daily clinical practice and its
potential effects on appropriateness of drug prescriptions after discharge from the hospital is unknown.
Methods/design: This is a prospective observational study. Patients ≥ 70 years with renal impairment (eGFR
<60 ml/min/1.73 m2) admitted to a geriatric ward are eligible to participate. Participants undergo blood sample
collection to measure serum creatinine level at three time points: at discharge from hospital, 14 days, and 2 months
after discharge. At these time points the actual medication of the participants is assessed and the number of
incorrect prescriptions according to the Dutch guidelines in relation to their estimated renal function is measured.
In addition, for a hypothetical selection of drugs, the need for drug dose adaptation in relation to renal function is
measured. The outcome of interest is the percentage of patients that changes from renal function group after
discharge from hospital compared to the renal function at discharge. In addition, the percentages of patients
whose actual medications are incorrectly prescribed and for the hypothetical selection of drugs that would have
required dose adaptation will be determined at discharge, 14 days and 2 months after discharge. For each
outcome, risk factors which may lead to increased risk for fluctuation of renal function and/or incorrect drug
prescribing will also be identified and analysed.
Discussion: This study will provide data on changes in renal function in elderly patients after discharge from the
hospital with a focus on the medications used. The benefits for healthcare professionals comprise of the creation,
adjustment or confirmation of recommendations for the monitoring of the renal function after discharge from
hospital of elderly patients.
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Background
Chronic kidney disease (CKD) is associated with an in-
creased mortality rate, as well as with an increased risk
of cardiovascular events and morbidity [1–3]. Because of
the longer life expectancy, due to improved treatment of
chronic diseases, the prevalence of impaired renal func-
tion increases [2–4]. In addition, there is a concern
about prescribing drugs, which need dose adjustment in
impaired renal function, especially in the elderly who are
at risk for impaired renal function [4].
Up to one-third of the adverse drug reactions (ADRs)
leading to hospital admission of elderly patients receiv-
ing outpatient care, may be related to impaired renal
function [5, 6]. The ADRs were serious, because they re-
sulted in or contributed to hospital admission. The
problems with ADRs, including ADRs not leading to
hospital admission, due to impaired renal function might
be even greater in ambulatory care. Therefore, the con-
sideration of renal function in ambulatory care drug
therapy management (DTM) should be improved [5–7].
The estimated glomerular filtration rate (eGFR) is im-
portant in the clinical management of patients [8]. It is
used for timely detection and management of declining
renal function, to adjust the dosage of renally excreted
drugs appropriately, and to avoid nephrotoxic drugs [1,
8, 9]. In the Netherlands, the eGFR is usually estimated
in daily clinical practice with the Modification of Diet in
Renal Disease (MDRD) formula. Dose adjustment of or
refraining from renally excreted drugs commonly takes
place categorically (see Table 1) [10].
In a hospital care setting a patient is closely observed
and (repeated) creatinine measurements are easy to per-
form. Informal clinical observations suggest that the
renal function may fluctuate so much that the renal
function group and therefore the recommended dose,
can change within a few days. A frequent scenario is that
the patient is dehydrated at hospital admission with im-
paired renal function and during hospital admission the
fluid balance is optimized and the eGFR increases.
The prevalence and the magnitude of fluctuations of the
renal function after discharge from the hospital are still
unknown. Since measurement of renal function is not rou-
tinely performed in the ambulatory care setting changes in
renal function may remain unnoticed. It is possible that
the eGFR may decrease, because of comprised fluid intake,
or may increase because of the patient’s further recovery.
Changes of renal function may lead to a shift to another
renal function group for drug dosing (see Table 1) and
thereby put patient at risk for not having optimal DTM.
This may have unwanted clinical consequences, such as
ADRs or insufficient effect. However, little is known about
the actual prevalence of such scenarios in daily practice.
The aim of this study is to describe the changes in es-
timated renal function in elderly patients 14 days and
2 months after discharge from hospital compared to the
value at discharge. Renal function will be classified ac-
cording to the categories, which are defined in relation
to DTM (see Table 1). In addition, incorrectly prescribed
drugs in the actual medications of the patient according
to the Dutch guidelines in relation to their renal func-
tion will be determined at discharge, 14 days and
2 months after discharge from hospital. Finally, the per-
centage of patients in whom the fluctuation would have
required another dosage regimen, if they had been tak-
ing a hypothetical selection of drugs that require dose
adaptation, will be determined. For each outcome, risk
factors for the fluctuation of renal function and for in-
correct prescribing will be examined.
Methods/design
This study is conducted according to the Declaration of
Helsinki. The study has been approved by the accredited
Medical Ethical Committee of Brabant (formerly:
METOPP). The Jeroen Bosch Hospital in ‘s-Hertogen-
bosch has provided local feasibility approval.
Study designs and setting
This study is a prospective observational study and will
be performed at the geriatric ward of the Jeroen Bosch
hospital (JBZ), which is a teaching top-clinical hospital
in The Netherlands serving 800 beds.
Study population
All consecutive patients ≥ 70 years with renal impair-
ment (eGFR <60 ml/min/1.73 m2 calculated with the
MDRD formula (eGFR)) at admission to the geriatric
ward will be asked to participate in the study. Further-
more, patients must remain community dwelling after
discharge from hospital for at least 2 months. Exclusion
criteria are patients with an eGFR < 10 ml/min/1.73 m2
and patients discharged for end-of-life care.
Patients eligible for the study will be invited and in-
formed by their geriatrician. Informed consent is obtained
by the researcher. In case the patient is incapacitated the
patients’ legal guardian will be informed through written
information and in case of participation the legal guardian
will sign the informed consent. Permission to request
the medication history at the community pharmacy will
be asked at the same time. Patients can leave the study at
Table 1 Renal function groups for drug dosing [10]
Group Description GFR (ml/min/1.73 m2)
1 Normal renal function >80
2 Mild renal impairment 50–80
3 Moderate renal impairment 30–50
4 Severe renal impairment <30
5 End stage renal disease (ESRD) Requiring dialysis
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The main study parameter is the eGFR(MDRD). Serum
creatinine level will be measured at 3 different time points,
at discharge, 14 days and 2 months after discharge.
The eGFR(MDRD) will automatically be calculated as
follows: 175  Scr‐1:154  age‐0:203  1:212 if blackð Þ 
0:742 if femaleð Þ [11].
The estimated renal function will be classified accord-
ing to the categories, which are commonly applied in re-
lation to DTM (see Table 1). The main endpoint is the
percentages of patients in whom the eGFR improves, de-
teriorates and remains unchanged within 2 months after
discharge compared to their eGFR at discharge.
Improvement is defined as a change to a better renal
function group as shown in Table 1 compared to the
renal function group at discharge. Deterioration is de-
fined as the change towards a worse renal function
group as shown in Table 1 compared to the renal func-
tion group at discharge. Unchanged is defined as no
change in renal function group.
Secondary study parameters
At each time point the recommended dose or contra-
indication for each drug the patient uses is determined
in accordance with the eGFR of the patient and the
Dutch guidelines for drug-dosing in chronic kidney dis-
ease [12]. A secondary endpoint will be the percentage
of patients in whom the prescribed drugs are not in ac-
cordance with the Dutch guidelines at discharge, 14 days
and 2 months after discharge from hospital.
Possible reasons for changes in the percentage of in-
correct prescribed drugs at the different time points will
be identified. Besides fluctuation of eGFR, other reasons
could be starting a new drug not adjusted to renal func-
tion or discontinuation of a drug, which needed adjust-
ment in renal impairment.
The average number of incorrectly prescribed drugs
per patient and the type of drugs most often incorrectly
prescribed at the three different time points will be
determined.
The top 10 most frequently prescribed drugs in the
elderly outpatients (>70 years) that require dose adapta-
tion in patients with renal impairment are selected from
the database of the Dutch foundation for pharmaceutical
statistics (see Appendix 1) (Table 3). The recommended
doses or contraindications of this hypothetical selection
of drugs will be determined at each time point in rela-
tion to the renal function of the patient and subse-
quently compared with the recommended doses or
contraindications at discharge. The endpoints will be the
percentages of patients in whom a change in the medica-
tion would be needed at 14 days and at 2 months after
discharge compared to the medication needed at
discharge.
Potential risk factors at admission and during admis-
sion which may predict fluctuation between renal func-
tion groups will be determined. These risk factors are
presented in Table 2.
Data collection
Table 2 shows the detailed data collection at each time-point.
When patients are admitted to the geriatric ward a
blood sample is almost always routinely taken for a range
of tests including serum creatinine value and C-reactive
protein (CRP).
Prior to discharge (max. 2 days) a blood sample will be
taken to measure serum creatinine. At discharge the pa-
tients are given two laboratory forms to collect blood
samples 14 days and 2 months after discharge to meas-
ure creatinine. The patient will be reminded to go to the
nearest general practitioners laboratory for blood sample
collection 14 days and 2 months after discharge. Initially
the blood samples were taken at the patient’s nearest
general practitioners laboratory. This was changed to
blood sample collection at home because patients often
did not show up at the laboratory.
At admission the following variables are collected as
part of usual care: age, gender, weight, length, use of
NSAIDs in the two weeks prior to admission, nutritional
status and hydration status. The nutritional status will
be defined with the Simplified Nutritional Appetite
Questionnaire (SNAQ) [13] and the hydration status will
be observed and judged by the physician.
The following parameters will be collected retrospect-
ively per patient: all creatinine values measured during
admission, admission via emergency department or a
planned admission, reason for admission (diagnosis),
duration of admission, co-morbidities, and medication
orders during admission.
After two months the researcher will obtain the medi-
cation history (from at least 6 months prior to discharge
to 2 months after discharge) of the patient from the
community pharmacy.
Measurement of serum creatinine
All blood samples (heparinized plasma) will be analyzed at
the Clinical Chemistry and Hematology department of
JBZ. Serum creatinine levels will be measured in blood
samples with the isotope dilution mass spectrometry
(IDMS)-traceable Jaffe method on a Dimension Vista
1500 system (Siemens Healthcare Diagnostics) [14].
The results of the creatinine measurements will be re-
ported to the general practitioner and/or the geriatrician
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as soon as the creatinine value is available. If necessary,
adjustment of the medication can be made according to
the Dutch guidelines by the general practitioner and/or
the geriatrician. Reporting the creatinine value will not
have an influence on the results. We will carefully exam-
ine the medication histories and identify changes made
after reporting the creatinine value.
Statistical power estimation
This study focuses on the fluctuation of renal function
in elderly patients within two months after discharge
from hospital. We are both interested in the percentage
patients that change from one to another renal function
group, but also in the direction of these changes (im-
provement or deterioration).
Raosoft sample size calculator (http://www.raosoft.com/
samplesize.html) was used to estimate the number of sub-
jects required to detect a change in renal function group
in 15 % of the population with a 95 % confidence level
and a 5 % margin of error. The recommended sample size
is 195 subjects.
In order to detect a difference in percentage of patients
in whom the change in renal function group improved
or deteriorated the sample size is calculated based on
the McNemar test (https://www.statstodo.com/SSizMcNe-
mar_Pgm.phpPgm.php). Assuming that 5 % of the patients
improve and 15 % of the patients deteriorate after discharge
from hospital, power (1-beta) is 0.8 and probability of type I
error (alpha) is 0.05, the sample size calculated is 155.
A sample size of 195 subjects should be sufficient for
answering both questions in this study. Assuming that
20 % of the included patients are lost to follow-up, the
number of patients needed to include is 195/0.8 = 244.
Statistical analysis
For each patient data will be collected and archived in a val-
idated data file. Errors and missing data will be monitored
during data-collection, and complemented or corrected
whenever possible. After completion of data-sampling, data
will be checked for logical consistency (e.g., out of reach
scores) and then finalised and locked. This file will be the
basis for all further data analyses.
Table 2 Data collection overview
Time-points
Parameter At admission At discharge 14 days after discharge 2 months after discharge
Serum creatinine level √ √ √ √







Admission via emergency department or planned admission √
Reason for admission (diagnosis) √
C-reactive protein (CRP) √
Duration of admission √
Co-morbidities √
Nutritional status (SNAQ-score) √
Hydration status √
All serum creatinine values measured during admission √
Specific items in medication history
• NSAID use 2 weeks prior to admission √
• Polypharmacy √
• Use and dose of diuretics √
• Use of NSAIDs √
• Use of RAS-inhibitors √
• Medications which influences creatinine productiona √
a These medications are: glucocorticosteroids, cimetidine, trimethoprim, fenofibrate (except gemfibrozil), calcitriol and alfacalcidol [22–24]
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To analyse if the percentages of patients in which the
renal function group improves, deteriorates and remains
unchanged 14 days and 2 months after discharge from
hospital compared to the renal function group at dis-
charge are statistically significant, the McNemar-Bowker
test will be used (categorical data with repeated mea-
surements within one patient).
The secondary outcome is the percentage of patients in
whom the prescribed drugs are not in accordance with the
Dutch guidelines. To test the differences of the concord-
ance of the medication to Dutch guidelines at the different
time points, the McNemar test will be used (binary data
with repeated measurements within one patient). The same
test will be used to analyse the percentage of patients in
whom a change in the medication would be needed if they
had been using the top 10 most frequently prescribed drugs
in elderly outpatients (>70 years) that require dose adapta-
tion in patients with renal impairment.
In further explorative analyses, we use various analyt-
ical methods (e.g., logistic regression analysis and nom-
inal logistic regression analysis) to identify potential
determinants of outcomes.
Discussion
DTM in patients with renal impairment is an important
issue. Efforts are being taken to reduce drug therapy errors
in these patients, for example by introducing clinical deci-
sion support systems [15, 16]. An educational intervention
providing a list of frequently used drugs and their dosing
schedule already reduced the number of drug dosing errors
[17]. Special attention should be paid to older patients with
renal insufficiency and polypharmacy who are using high
risk medications such as anticoagulants (e.g., vitamin K an-
tagonists, direct oral anticoagulants (DOAC)), diuretics,
cardiovascular agents, analgesics, and anti-diabetic agents
[18, 19]. All these studies and recently published guidelines
for drug dosing in renal impairment reflect on our daily
clinical practice in a hospital care setting. Every time when
a new eGFR is reported the correct drug or drug dose is
reviewed by the hospital pharmacist. Advices may change
from one day to another.
Guidelines, such as KDIGO, do not offer advice about
monitoring of the renal function after hospital discharge
[20, 21]. In addition, it is tempting for community pharma-
cists and general practitioners to rely on the latest eGFR
measured in the hospital for DTM after discharge. It is un-
certain how stable the eGFR is in elderly patients who have
recently been admitted to the hospital. This might be espe-
cially the case when eGFR changes were frequent during
hospital admission. This study is designed to address the
gap in monitoring the natural course of the renal function
after discharge from the hospital with attention to the med-
ications used in the elderly. If fluctuation of the eGFR is
present at great extent this study will address whether
closer monitoring of renal function and adaptation of ren-
ally excreted drugs after discharge will be needed. In
addition, the benefits for healthcare professionals comprise
of creation, adjustment or confirmation of recommenda-
tions for monitoring renal function after discharge from
hospital of elderly patients.
Appendix 1: Top 10 most frequently prescribed
medications in elderly patients
Table 3 Top 10 most frequently prescribed drugs in the elderly
outpatients (≥70 years) that require dose adaptation in patients
with renal impairmenta
Drug Dosing advice in renal impairment
1 furosemide 10–30 ml/min
Starting dose as in normal renal function.
If necessary, increase the dose guided by
effect and indication.
In case the effect is inadequate, replace
furosemide by bumetanide.
2 metformin 30–50 ml/min
Starting dose 2 × 500 mg metformin




3 hydrochlorothiazide 10–30 ml/min
Avoid hydrochlorothiazide
4 enalapril 30–50 ml/min
Starting dose is 5 mg once daily.
If necessary, increase the dose guided by
clinical effect.
If the prescriber is a general practitioner
the maximum dose is 10 mg.
If the prescriber is a specialized physician
the dose may be higher.
10–30 ml/min
Starting dose is 2.5 mg once daily.
If necessary, increase the dose guided
by clinical effect.
If the prescriber is a general practitioner
the maximum dose is 5 mg.
If the prescriber is a specialized physician
the dose may be higher.
5 perindopril 30–50 ml/min
If the prescriber is a general practitioner
the maximum dose is 2 mg.
If the prescriber is a specialized physician
the dose may be higher.
10–30 ml/min
If the prescriber is a general practitioner
the maximum dose is 2 mg every 48 h.
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